Nicotine pouches and the question we have not asked: what FDA’s pending ZYN decision tells us about substance policy

In January 2025, ZYN became the first nicotine pouch product to receive marketing authorization from the FDA through the Premarket Tobacco Product Application pathway, with 20 SKUs cleared — the Chill, Cinnamon, Citrus, Coffee, Cool Mint, Menthol, Peppermint, Smooth, Spearmint, and Wintergreen lines, in 3 mg and 6 mg strengths. That decision turned a product previously living in regulatory ambiguity into a fully PMTA-authorized tobacco product with the federal government’s clearance to be marketed and sold.

A year later, Philip Morris International is asking for something more. The Modified Risk Tobacco Product application before the FDA is asking the agency to authorize PMI to advertise ZYN with the explicit claim that “using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” On January 22, 2026, the FDA’s Tobacco Products Scientific Advisory Committee reviewed the application and the agency itself said publicly that “the evidence suggests the proposed modified risk claim is scientifically accurate.”

Final FDA action is pending. There is no public timeline.

This is, on its face, a tobacco-regulation story. It is more than that.

The science the FDA already evaluated

PMI’s MRTP application is built on a body of toxicology, pharmacokinetic, and population-level evidence comparing nicotine pouches with combustible cigarettes. The honest summary: pouches deliver nicotine without combustion. Combustion is what produces the bulk of the carcinogens, particulate matter, and cardiovascular insults that make smoking the leading preventable cause of death in the United States. Removing combustion does not remove all risk. It removes a category of risk.

That is what FDA staff appear to have concluded, on the narrow scientific question. The “lower risk than cigarettes” claim is comparative, not absolute. It does not say pouches are safe. It does not address risk for adolescents, pregnant people, or people with cardiovascular disease. It does not address the risk of dependence — only the risk of disease compared with smoking.

The TPSAC role is advisory. The FDA can authorize, modify, or reject the claim regardless of what the committee recommends. Tobacco Reporter notes that decisions of this scale typically take months.

The harm-reduction frame, applied to nicotine

For the SUD field, the framework here is not actually new. It is the same framework that animates naloxone distribution, syringe service programs, and methadone maintenance: the goal is to reduce the population-level harm associated with a substance, in part by giving people access to a less-dangerous version of the thing they are already using.

The complication: nicotine has a very different population profile than opioids or alcohol. The lethality of nicotine, in the absence of combustion or vape-cart contaminants, is low. Most of the public-health damage from nicotine in the United States comes from the smoke that the nicotine arrives in, not from the nicotine itself. That is what makes the comparative claim defensible. It is also what makes the policy fight messier than the harm-reduction precedent in opioids — because the population the modified-risk framing is most useful for (current adult smokers) overlaps imperfectly with the population most susceptible to new uptake (young adults, including those who never smoked).

Less than 1% of US adults currently use nicotine pouches. Pouches are the fastest-growing segment of the tobacco market. ZYN alone posted $3.24 billion in sales last year — more than two-thirds of the entire pouch category. That growth is not coming primarily from former smokers switching. It is coming from new users, many of them young, many of them in subcultures (sports, finance, gaming) where pouches are increasingly normalized.

ZYN alone posted $3.24 billion in sales last year — more than two-thirds of the entire pouch category.

Recent developments

The FDA’s March 9 framework on flavored ENDS — being applied to April enforcement against illegal disposable imports — is happening in parallel and reflects the same agency trying to balance combustible-displacement and youth-uptake at the same time, on a different product.

Treatment infrastructure has not caught up. Most quit-line, MAT, and behavioral telehealth platforms — Pelago, Quit Genius, Truth Initiative resources, Achieve Wellness — were built around combustible cigarettes and, more recently, e-cigarettes. Pouches require some adaptation: the cessation pharmacotherapy (varenicline, NRT) is the same, but the trigger landscape, the use-pattern data, and the relapse-prevention conversation have specifics. Some platforms have added pouch-specific content. Many have not.

The “modified risk = healthier” interpretation in lifestyle and sports communities is already running ahead of any formal MRTP authorization. That is a public-communication risk regardless of what the FDA ultimately decides.

Where the field disagrees

There is genuine and respectful disagreement, even among researchers who broadly support tobacco harm reduction, about three things:

Whether MRTP authorization on this product, at this moment, will accelerate combustible-cigarette decline or normalize a new generation of nicotine dependence — and whether the empirical answer is even knowable in advance.

Whether population-level health gains from a switch-from-cigarettes effect outweigh population-level health and dependence costs from new-user uptake.

Whether nicotine itself, separated from combustion, deserves the same regulatory and public-health posture as other addictive substances, or a substantially less restrictive one.

Reasonable people read the same data and land in different places. The MRTP authorization framework is, by design, an attempt to let the FDA acknowledge a comparative risk without endorsing the underlying product. Whether that distinction translates to consumers is the empirical question that will play out over the next several years.

Why this matters for people in recovery

If you are in recovery from any substance and you currently use ZYN or another nicotine pouch, the question worth asking is not “is this the right way to quit smoking” — that question has a fairly clear answer in your individual case (talk to your prescriber). The question worth asking is whether your nicotine use is doing what you want it to do in your life, and whether you would like it to stop being a thing you depend on. Cessation pharmacotherapy works. Behavioral support works. Both work better together. Pouches are no easier to quit than cigarettes once dependence is established — most people underestimate this.

If you do not currently use nicotine in any form, the modified-risk framing is not an invitation. It is a policy conversation about the population of people who already do.

Resources

If you want help cutting back or quitting nicotine in any form: 1-800-QUIT-NOW connects you to your state’s free quit line. Most state lines offer NRT, behavioral coaching, and follow-up calls at no cost. Your primary care provider can prescribe varenicline (Chantix) or bupropion (Zyban) if appropriate.

---

If you or someone you love is in immediate danger, call or text 988 (Suicide & Crisis Lifeline) or 911. SAMHSA’s 1-800-662-HELP (4357) is free, confidential, and available 24/7.